Videos

Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.

Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.

Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.